Eterna Therapeutics Inc (ERNA)vsModerna Inc (MRNA)
ERNA
Eterna Therapeutics Inc
$2.11
+6.57%
HEALTHCARE · Cap: $3.44M
MRNA
Moderna Inc
$214.17
+2.98%
HEALTHCARE · Cap: $87.04B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 222799900% more annual revenue ($2.23B vs $1,000). ERNA leads profitability with a 0.0% profit margin vs -141.4%. ERNA earns a higher WallStSmart Score of 24/100 (F).
ERNA
Avoid24
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-77.7%
Fair Value
$0.17
Current Price
$2.11
$1.94 premium
Margin of Safety
+69.9%
Fair Value
$134.71
Current Price
$214.16
$79.45 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Trading at 12.6x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ERNA
The strongest argument for ERNA centers on Price/Book, Debt/Equity.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : ERNA
The primary concerns for ERNA are EPS Growth, Market Cap, Profit Margin.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
ERNA profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
ERNA carries more volatility with a beta of 2.65 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
ERNA generates stronger free cash flow (-4M), providing more financial flexibility.
Bottom Line
ERNA scores higher overall (24/100 vs 21/100). MRNA offers better value entry with a 69.9% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eterna Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Brooklyn ImmunoTherapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat cancer patients. The company is headquartered in Brooklyn, New York.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?